Atrial Fibrillation Stocks List

Atrial Fibrillation Stocks Recent News

Date Stock Title
May 3 BSGM BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent
May 3 BMY Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
May 3 MDT Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
May 3 BMY If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
May 3 BMY The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
May 3 BMY Bristol-Myers Squibb: A Lost Decade?
May 2 BMY Schrodinger gets rights to cancer drug candidate back from Bristol
May 2 BMY Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
May 2 MDT Shareholders in Medtronic (NYSE:MDT) are in the red if they invested three years ago
May 1 MDT Medtronic recalls SonarMed Airway sensors over safety concerns
May 1 BMY Editas, Bristol Myers extend T cell therapy collaboration
May 1 MDT Medtronic: 'Pivotal Moment' in Women's Heart Health
May 1 BMY Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 1 ITGR Integer to Present at 2024 Bank of America Securities Healthcare Conference on May 14
Apr 30 BSGM BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
Apr 30 BMY Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Apr 30 BMY J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations
Apr 30 ITGR Integer Holdings Corporation (NYSE:ITGR) Q1 2024 Earnings Call Transcript
Apr 30 BMY Bristol Myers Squibb: Tough Times Continue
Apr 29 BMY J&J, Bristol Myers lose challenges to US drug price negotiation program
Atrial Fibrillation

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

Browse All Tags